Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
100 participants
INTERVENTIONAL
2006-09-30
2008-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The aim of our single center randomized study is to evaluate the early and late effect of thrombus aspiration device (AD) after every stage during Primary PCI in the set-up of STEMI population.
Our hypothysis is that preforming thrombus aspiration after every stage of primary PCI may give early and late advantages compared to the standard primary PCI technique.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Standard PCI versus Primary PCI, using thrombus aspiration device after ever step of the procedure.
Issues to be examined are:
1. Immediate angiographic differences between the study arms. By evaluation of: TIMI FLOW GRADE,TIMI FRAME COUNT,MYOCARDIAL BLUSH GRADE. No reflow phenomenae,
2. Infarc size evaluated by serum markers and non invasive parameters
3. In hospital major adverse cardiac events
4. Major adverse cardiac events during 30\& 180 days of follow up
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
repeated thrombus aspiration during primary PCI
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* eligble for primary PCI regardless of initial TIMI flow grade.
* patients for rescue PCI after failed thrombolysis will also be included
Exclusion Criteria
* pts with allergy to aspirin, clopidogrel or heparin
* inability to obtain informed consent
* known existence of life threatening diseases with a life expectency less than 6 months
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
HaEmek Medical Center, Israel
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yoav Turgeman, MD
Role: PRINCIPAL_INVESTIGATOR
Technion-school of medicine, Haifa, Israel
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
HaEmek Medical Center
Afula, , Israel
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Yoav Turgeman MD
Identifier Type: -
Identifier Source: secondary_id
HaE064990ctil
Identifier Type: -
Identifier Source: org_study_id